Model N investing in India to support Asia Pacific growth

By Nick Taylor

- Last updated on GMT

US-based Model N is to invest up to Rs 100 crore ($21m) in its Indian operations to meet growing demand for its revenue management services.

Model N has experienced an upturn in business over the past 18 months, inking deals with a number of leading biopharm and generics firms, and is expanding global operations to meet demand.

Relocation to a new facility in DLF Cyber City, Hyderabad, India will support the expansion. Model N, which currently has 100 India-based staff, plans to hire 40 additional employees for the Hyderabad site in the immediate future. Over the next 18 months the total could increase to 250.

Staff will be added in the areas of product development, professional services and customer support services. Model N intends to invest Rs 80 to 100 crores over the next three years to fund the expansion.

Srikanth Gadamsetty, general manager, Model N India, said the expansion will “enable us to more easily scale to meet the needs of the increasingly globalised life science and high tech industries​”. The Hyderabad site will support clients based throughout Asia Pacific.

Model N’s decision to base its Asia headquarters in Andhra Pradesh was underpinned by the regional government’s efforts to attract pharma. Konijeti Rosaiah, chief minister of Andhra Pradesh, said the region’s “industry-friendly measures​” support long-term investment.

US expansion

California-based Model N is also expanding its US operations. The company is “aggressively hiring​” in all areas of the business to increase total staffing levels by 20 per cent by the end of September.

This has been accompanied by a reorganisation of its leadership structure. By promoting key employees, creating new functions and adding executive leadership Model N believes it will have the personnel and structure to support further expansion.

Related news

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Follow us


View more